Upcoming IPO: Integrity Infrabuild Developers, Accretion Pharmaceuticals Infotech to Launch IPOs

Two companies are preparing to launch their upcoming IPOs in the second week of May 2025 Integrity Infrabuild Developers and Accretion Pharmaceuticals Infotech. The combined issue size stands at ₹41.75 crore.

Integrity Infrabuild Developers IPO 

Mumbai-based infrastructure firm Integrity Infrabuild Developers is set to raise ₹12 crore through a fixed price issue. The IPO will consist solely of a fresh issue of 12 lakh equity shares, each priced at ₹100. The public offering will open on May 13, 2025, and close on May 15, 2025. 

As per the company’s prospectus, the IPO proceeds will be used for the acquisition of new construction machinery and equipment to support ongoing and future infrastructure projects. A portion of the funds will also be allocated toward operational expenses, including project execution, procurement of raw materials, and labor payments, ensuring business continuity. Any remaining funds will be directed toward general corporate purposes. 

Accretion Pharmaceuticals Infotech IPO 

Accretion Pharmaceuticals Infotech, a healthcare-focused company, is launching a ₹29.75 crore IPO via a fresh issue of 29.46 lakh equity shares. The IPO is priced as a fixed issue and will open for public subscription on May 14, 2025, closing on May 16, 2025. 

According to its draft filing, the company plans to use the raised capital to enhance its manufacturing infrastructure across various pharmaceutical forms, including tablets, capsules, oral liquids, and topical formulations. Additionally, part of the proceeds will be used to scale up contract manufacturing operations, supporting both domestic expansion and international demand fulfillment. 

Read More: SEBI Plans Major Changes in F&O Rules to Ease Trading and Improve Risk Monitoring. 

Conclusion 

With both IPOs opening in mid-May, Integrity Infrabuild Developers and Accretion Pharmaceuticals Infotech aim to strengthen operations, scale infrastructure, and tap into capital markets for growth. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.